Table 3.

Multivariate analysis including all patients (n = 44,498)

		Hazard Ratio	95% Confidence Interval	p-value
Sex	Male	1.00	Ref	< 0.0001
	Female	0.82	0.80–0.84
Age	18–59	1.00	Ref	< 0.0001
	60–69	1.02	.099–1.05
	70–79	1.05	1.02–1.08
	80+	1.15	1.10–1.20
Comorbidity	0	1.00	Ref	< 0.0001
	1	1.08	1.05–1.10
	> 2	1.23	1.19–1.28
Histology	Adenocarcinoma	1.00	Ref	< 0.0001
	Non-adenocarcinoma	1.14	1.12–1.16
Race	White	1.00	Ref	< 0.0001
	Non-white	0.88	0.85–0.91
Insurance	Uninsured	1.00	Ref	0.012
	Insured	0.92	0.88–0.98
Facility Type	Academic	1.00	Ref	< 0.0001
	Nonacademic	1.16	1.13–1.18
Systemic Therapy	Chemotherapy	1.00	Ref	< 0.0001
	Immunotherapy	0.81	0.78–0.84
Radiation	No Radiation	1.00	Ref	< 0.0001
	EBRT	1.16	1.13–1.18
	SRT	0.73	0.69–0.78